Menu Search
Equities

Novartis AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NOVNEE:SWX

Novartis AG

Actions
  • Price (CHF)92.20
  • Today's Change-0.83 / -0.89%
  • Shares traded400.00k
  • 1 Year change-3.43%
  • Beta--
Data delayed at least 15 minutes, as of Jul 18 2025 15:42 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NOVN:SWX since
announced		Transaction
value
Regulus Therapeutics IncDeal completed30 Apr 202530 Apr 2025Deal completed-2.04%1.62bn
Anthos Therapeutics IncDeal completed11 Feb 202511 Feb 2025Deal completed-4.80%3.08bn
Data delayed at least 15 minutes, as of Jul 18 2025 16:31 BST.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Massachusetts Financial Services Co.as of 31 May 2025292.25k0.00%
LUKB Expert Fondsleitung AGas of 31 Jul 202482.29k0.00%
Voya Investment Management Co. LLCas of 30 May 202544.46k0.00%
Pyrford International Ltd.as of 31 Dec 202444.45k0.00%
N.F.U. Mutual Unit Managers Ltd.as of 30 Jun 202318.42k0.00%
Nomura Asset Management Co., Ltd.as of 30 Jun 202511.99k0.00%
Skyblue Fund Managers (Pty) Ltd.as of 31 Mar 20256.00k0.00%
Columbia Threadneedle Management Ltd.as of 30 Sep 2024972.000.00%
Morgan Stanley AIP GP LPas of 30 Jun 2024237.000.00%
GAM Investment Management (Switzerland) AGas of 30 Apr 20250.000.00%
More ▼
Data from 30 Jun 2023 - 30 Jun 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.